文献速递类风湿关节炎

达标治疗策略缩短类风湿关节炎女性妊娠时间

Time to pregnancy in women with rheumatoid arthritis who want to conceive treated according to a treat-to-target approach: a comparison of an observational cohort with a historical reference cohort.
PubMed 文献 · Lancet Rheumatol · 2026-03-26

达标治疗与妊娠时间缩短相关,接近一般人群水平。

核心结论

  • 达标治疗策略与类风湿关节炎女性妊娠时间缩短相关,接近一般人群水平。

研究设计与样本

  • 比较性研究,PreCARA前瞻观察队列(2011年9月至2023年9月,n=215)接受达标治疗,PARA历史前瞻观察队列(2002年5月至2010年8月,n=245)未采用该策略,均在荷兰Erasmus大学医学中心开展。

临床怎么用

  • 对有妊娠意愿的类风湿关节炎女性,可采用达标治疗策略,避免NSAIDs及高剂量泼尼松,使用妊娠兼容药物。

局限性

  • 研究为观察性比较,非随机对照,历史对照队列时间跨度不同,可能存在时代偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Time to pregnancy is prolonged in women with rheumatoid arthritis. Rheumatoid arthritis-related factors that influence time to pregnancy include high disease activity, high daily prednisone intake (exceeding 7·5 mg), and non-steroidal anti-inflammatory drug (NSAID) use. The aim of this study was to investigate whether a treat-to-target approach aimed at remission, while avoiding NSAIDs and high doses of prednisone, was associated with a reduced time to pregnancy in women with rheumatoid arthritis who wanted to conceive. METHODS: This comparative study used data from a prospective observational cohort of patients treated with a treat-to-target approach and a historical prospective observation cohort that did not use this approach. Cases were derived from Preconception Counseling in Active Rheumatoid Arthritis (PreCARA; September, 2011, to September, 2023) and controls from Pregnancy-Induced Amelioration of Rheumatoid Arthritis (PARA; May, 2002 to August, 2010). Both studies were conducted at the Erasmus University Medical Center in The Netherlands and women with rheumatoid arthritis who wanted to conceive or were already in their first trimester were eligible. In PreCARA, participants were managed according to treat-to-target principles adapted for pregnancy. The treat-to-target approach avoided NSAIDs and prednisone use over 7·5 mg per day and medication compatible with pregnancy was provided (eg, TNF inhibitors). The primary outcome was the occurrence of pregnancy and time to pregnancy in all participants, calculated as the duration between the date of the first attempt to conceive and the first day of the last menstrual period before pregnancy. People with lived experience were involved in the design of both PreCARA and PARA. FINDINGS: 215 patients from PreCARA and 245 patients from PARA were included. The mean age in PreCARA was 32·4 years (SD 4·2) and in PARA it was 31·8 years (3·9). Patients in PreCARA had a median time to pregnancy of 91 days (IQR 27-333), compared with 251 days (IQR 97-554) in the PARA cohort (p<0·0001). 165 (77%) of 215 patients in PreCARA got pregnant within 1 year versus 103 (42%) of 245 patients in PARA (p<0·0001). 131 (61%) of 215 patients in PreCARA reached clinical remission. Their median time to pregnancy was 65 days (IQR 19-295), compared with 150 days (IQR 49-575) in patients in PreCARA who did not reach remission (p=0·0054). INTERPRETATION: This study showed that, in women with rheumatoid arthritis treated according to a treat-to-target strategy, time to pregnancy was reduced and was close to that of the general population. FUNDING: Dutch Arthritis Foundation and UCB.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Quaak CH, Röder E, Wintjes HM, et al. Time to pregnancy in women with rheumatoid arthritis who want to conceive treated according to a treat-to-target approach: a comparison of an observational cohort with a historical reference cohort. Lancet Rheumatol. 2026. PMID: 41905370. doi:10.1016/S2665-9913(26)00001-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。